Biological explanations for discordant noninvasive prenatal test results: Preliminary data and lessons learned
Open Access
- 6 April 2018
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (6) , 445-458
Abstract
Objective: Maternal plasma cell‐free DNA (cfDNA) analysis is a powerful screening tool for Down syndrome. In a pilot series, we examined biologic causes of discordance between the cfDNA test results and the fetal karyotype. We also explored the feasibility of obtaining trio biospecimens by using parental engagement.Methods: A convenience sample of women with discordant cfDNA results were recruited by their care providers. We provided shipping materials and instructions for biospecimen collection. Maternal, newborn, and placental samples were examined with droplet digital PCR.Results: Thirteen of 15 women successfully had biospecimens obtained remotely. High‐quality DNA was extracted in 12 of 13 women. Presumed biologic etiologies for discordance were identified in 7 of 12 women: 3 cases from additional clinical review (male renal transplant, vanishing twin, and colon cancer) and 4 cases from additional laboratory investigation using droplet digital PCR (3 with confined placental mosaicism and 1 with true fetal mosaicism).Conclusions: Understanding the biology behind cfDNA‐fetal karyotype discordancy is useful for follow‐up clinical care. Our study suggests that most cases could be resolved by using a trio biospecimen protocol and parental involvement. To improve accuracy, additional sequencing of biospecimens will be required.Keywords
This publication has 57 references indexed in Scilit:
- Positive cell-free fetal DNA testing for trisomy 13 reveals confined placental mosaicismGenetics in Medicine, 2013
- Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samplesPrenatal Diagnosis, 2013
- Clinical application of massively parallel sequencing‐based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factorsPrenatal Diagnosis, 2012
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative studyGenetics in Medicine, 2012
- Selective analysis of cell‐free DNA in maternal blood for evaluation of fetal trisomyPrenatal Diagnosis, 2012
- Universal noninvasive detection of solid organ transplant rejectionProceedings of the National Academy of Sciences, 2011
- Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical settingAmerican Journal of Obstetrics and Gynecology, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011
- Confined placental mosaicism as a risk factor among newborns with fetal growth restrictionPrenatal Diagnosis, 2006